) fourth quarter 2012 adjusted earnings (including stock-based
compensation) of 3 cents per share were above the Zacks Consensus
Estimate of a penny but significantly lower than the year-ago
earnings of 51 cents.
The year-over-year earnings decline was primarily due to lower
Quarterly revenues, which decreased 26.8% year over year to
$106.5 million, beat the Zacks Consensus Estimate of $104
million. The decline in revenues was primarily due to decreased
Vancocin sales in the face of generic competition, which was
partially offset by growth in Cinryze sales.
For 2012, revenues came in at $427.9 million, down 21.4% from
2011 and in line with Zacks Consensus Estimate. Cinryze accounted
for $327.1 million of total sales in 2012. Cinryze sales came in
line with management expectations.
Approximately $311 million of total Cinryze sales was
attributed to actual patient demand while an increase in channel
inventories accounted for the remainder.
Adjusted earnings of 16 cents per share in 2012 were a penny
short of the Zacks Consensus Estimate.
Cinryze sales increased 45% from the prior-year quarter to
$97.0 million during the final quarter of 2012, driven by higher
On the other hand, Vancocin net sales plummeted 93.4% in the
quarter to $5.0 million, down from $77.8 in the year-ago quarter.
The decline was attributable to the presence of generic
vancomycin capsules in the US market.
Research and development (R&D) expenses increased 50.6%
during the quarter to $19.1 million.
Selling, general and administrative (SG&A) expenses
amounted to $50.9 million, up 41.5% from the prior-year quarter
due to costs related to the launch of Cinryze, Buccolam and
Plenadren in the EU and additional Cinryze commercialization
costs in the U.S.
During 2012, ViroPharma repurchased 6.9 million shares for
ViroPharma provided its guidance for 2013. The company expects
net product sales in a range of $450 - $475 million. The company
maintained its US Cinryze sales guidance of $390-$400
Further, ViroPharma continues to expect combined R&D and
SG&A expenses in the range of $240 - $260 million.
ViroPharma is also upbeat about its pipeline. The company and
) initiated a phase IIb study in late December 2012 to evaluate
the safety and efficacy of a subcutaneous administration of
Cinryze in combination with Halozyme's Enhanze technology.
ViroPharma carries a Zacks Rank #3 (Hold). Currently,
Avanir Pharmaceuticals Inc
) look well placed with a Zacks Rank #2. (Buy).
AVANIR PHARM (AVNR): Free Stock Analysis
BAYER A G -ADR (BAYRY): Free Stock Analysis
HALOZYME THERA (HALO): Free Stock Analysis
VIROPHARMA (VPHM): Free Stock Analysis Report
To read this article on Zacks.com click here.